Day: 14 6 月, 2025

HONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - Tat Hong Equipment Service Co., Ltd. (“Tat Hong” or the “Company”, together with its subsidiaries, the “Group”) (Stock Code: 2153), the first foreign-owned tower crane service provider established in the PRC, has announced its annual results for the year ended 31 March 2025 (“FY2025” or the “Year”).In FY2025, the Group recorded revenue of approximately RMB 634.6 million (2024: RMB682.3 million). Loss attributable to equity holders of the Company for the year ended 31 March 2025 amounted to RMB 120.5 million (2024: RMB95.6 million). The increase in loss was primarily due to (i) slower economic growth and a downturn in the construction industry led to a decline in revenue; and (ii) the adjustment of deferred tax resulted in increased income tax expenses.As at 31 March 2025, the Group is managing a total of 1,180 tower cranes. The Group’s total tonne metres (TM) in use decreased from 3,178,404 for the year ended 31 March 2024 to 3,137,910 for the year ended 31 March 2025. As at 31 March 2025, the Group had 256 projects in progress with a total outstanding contract value of approximately RMB 721.4 million and 38 projects on hand of total expected contract value at approximately RMB 78.7 million.During the financial year, under the effect of insufficient market demand and the decline in the average monthly service price of tower cranes per TM, the supply and demand mismatch had resulted in high market competition in the entire construction machinery industry. To cope with the sluggish market conditions, the Group has developed tailored strategies and continuously adjusted its business mix, progressively reducing the revenue contribution from the real estate sector.In response to the national initiative to vigorously develop clean energy and aligning with market trends and growth potential, the Group has concentrated on thermal power projects and nuclear power projects. Clean energy projects usually entail lengthy construction cycles and large-scale operations, and the Group has obtained significant advantages by leveraging its extensive industry experience, established construction expertise, and strong technical capabilities.In FY2025, the Group accelerated its overseas market presence, thoroughly implemented its operational strategies through its subsidiaries in the Greater Bay Area and in Indonesia, and gradually expanded its fleet of large and medium-sized tower cranes. Up to now, large-tonnage-meter tower cranes have been predominantly deployed in the projects across Hong Kong and Indonesia. In light of the above, clean energy and overseas projects remain the Group’s key priorities for future development.During the year, the Group had continued the investment in the digitalization of the management platform and the research and development of new tower crane technical solutions. As at 31 March 2025, the Group possess 187 registered patents for utility models and inventions relating to tower cranes. The robust technical capabilities will continue to enable the Group to procure projects, and the enhancement in the research and development capabilities for tower crane technical solutions will reinforce the excellent delivery in services.Mr. Sean Yau, CEO of Tat Hong Equipment Service Co., Ltd., said: " In addition to the downturn in the property market and the construction industry, the geopolitical tensions and the depreciation pressure on the RMB further weakened the economy of the PRC. Tackling these economic challenges and the changing business environment., we have promptly adopted adjustments to our development strategies, including the expansion to the clean energy construction segment and the geographical expansion to the Greater Bay Area and Indonesia, and we believe the positive impact will be reflected in the coming years.Mr. Roland Ng, Chairman of Tat Hong Equipment Service Co., Ltd., said: “In the most trying circumstances, we remain steadfast in our original mission. Guided by our core corporate values ‘Virtue , Safety and Excellence , we will continue to excel in our business endeavors. In the coming financial year, we will continue to further strength our position in the above new segments and locations, and seize new opportunities in the market, so as to concentrate on the research and development of new tower crane technologies to equip ourselves with the most robust technical capabilities to deliver excellent services to our clients. Furthermore, we will also continue to achieve resources sharing, cost reduction and efficiency enhancement. With all the above measures, we believe we can fulfil the Group’s goal to become ‘the best construction equipment service provider’ in the industry.”About Tat Hong Equipment Service Co., Ltd. (Stock Code: 2153)Tat Hong Equipment Service Co., Ltd. is the first foreign-owned tower crane service provider established in the PRC. Since 2007, the Group has established as a tower crane service provider for one-stop tower crane solution services from consultation, technical design, commissioning, construction to after-sales services primarily to Chinese Special-tier and Tier-1 EPC contractors. Guided by its core values, “Virtue, Safety and Excellence”, the Group has successfully established its market position and maintained stable, reputable and loyal customer base in the construction industry in the PRC.Media EnquiriesStrategic Financial Relations LimitedHeidi SoTel:(852) 2864 4826Email: heidi.so@sprg.com.hk Mel LaiTel:(852) 2864 4855Email: mel.lai@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - With the national strategy of “new quality productive forces” driving high-quality development, Yee Hop Holdings Limited (“Yee Hop Holdings”; stock code: 1662.HK) subsidiary Absolute Pure EnviroSci Limited (“APEL” or “the Company”) is actively aligning with national policies. It has recently established a Microfactory in collaboration with the Hong Kong Productivity Council (“HKPC”) to industrialize the patented Wisepura Aquapura porous silica capsule technology in Hong Kong, promoting smart manufacturing and new industrialization. The HKPC’s Life & Health Tech Hall, which opened in March this year, showcases over 20 research achievements and innovative applications developed by the HKPC, InnoHK, local universities, and industry partners, including the patented Wisepura Aquapura porous silica capsule technology.The World’s First Wisepura Aquapura Microfactory Fully OperationalAs a significant achievement of the collaboration, the world’s first Wisepura Aquapura Microfactory, developed in collaboration between APEL and HKPC, was officially launched on 13 June 2025 in Kowloon Bay, Hong Kong. This marks the successful implementation of the first phase of “Industry 4.0” and a significant milestone in the industrialization of APEL’s research achievements. During the inauguration ceremony, attended by numerous guests from the investment and business sectors, Mr. Jackin Jim, Chairman of Yee Hop Holdings, Dr. David Chung, Chairman of APEL, and Dr. Pat Yeung, Director of APEL, jointly unveiled the Microfactory, officially announcing its commencement of operations.Dr. Pat Yeung, Director of APEL (first from the left), Mr. Jackin Jim, Chairman of Yee Hop Holdings (second from the left), Mr. Mohamed Butt, Executive Director of HKPC (second from the right), and Dr. David Chung, Chairman of APEL (first from the right) are pictured together at the Wisepura Aquapura Microfactory Inauguration Ceremony.Dr. David Chung, Chairman of APEL, said, “We are honored to collaborate with HKPC in establishing the Wisepura Aquapura Microfactory, and we would like to extend our heartfelt gratitude to HKPC for their support. This collaboration highlights our strong research and innovation capabilities in the field of life and health technology. The official commencement of production at the APEL Wisepura Aquapura Microfactory enhances our ability to meet the growing market demand and injects new momentum into the company’s development. Looking ahead, we will continue to expand our network of partners and actively pursue international opportunities, endeavoring to bring local research achievements to the global stage and contribute to global health and environmental protection, working together for a sustainable future.”Dr. David Chung, Chairman of APEL, delivers a speech at the inauguration ceremony.Establishes Strategic Partnership with Shanhu Group to Explore New Opportunities in Water Purification and Aquaculture Technology in the Greater Bay AreaGuangdong Shanhu Group Co., Ltd. (“Shanhu Group”), a global leader in indoor air environment solutions, has seen its core product, industrial fans, gain widespread popularity across six continents, serving over 50 million users. Since 2015, Shanhu Mechanical and Engineering Co., Ltd., a subsidiary of Shanhu Group, has taken a forward-looking approach in the research and development (R&D) of intelligent and energy-saving technologies for aquaculture machinery. On 13 June 2025, APEL officially signed a strategic Memorandum of Understanding (MoU) with Shanhu Group to jointly enter the water purification and intelligent aquaculture sectors. The collaboration aims to develop advanced solutions for high-demand applications such as water purification equipment, ecological restoration technologies, and smart monitoring systems. These innovations will target environmental projects including river remediation, black and odorous water treatment, and ecosystem rehabilitation. Additionally, the partnership will address the stable demand for new filtration materials, water treatment processes, and water quality monitoring technologies in municipal wastewater treatment plants and industrial park facilities. The two companies will also establish cooperative relationships with government environmental agencies and municipal engineering firms to participate in wastewater treatment project bids and provide customized solutions.The collaboration encompasses technological R&D, market expansion, and resource sharing. The two parties will jointly develop intelligent water quality monitoring systems, leveraging big data and artificial intelligence (AI) to optimize aquaculture decision-making while promoting high-efficiency purification technologies for environmental engineering and municipal wastewater treatment markets. The project will integrate Shanhu Group's expertise in electromechanical equipment and disinfection technologies with APEL's proprietary Wisepura Aquapura Microfactory water treatment solutions. This one-year agreement, renewable upon expiration, will initially focus on deploying the collaborative achievements in the Guangdong-Hong Kong-Macao Greater Bay Area through business and technical exchange forums. The partnership is expected to drive the advancement of environmental protection and aquaculture industries in the region, fostering industrial chain transformation. Looking ahead, the collaboration aims to gradually expand into overseas markets.APEL (left) and Shanhu Group sign a strategic Memorandum of Understanding.Advancing towards a new era of “Industry 4.0” with smart manufacturingIn advancing “Industry 4.0” initiative, the APEL Wisepura Aquapura Microfactory integrates cutting-edge technologies such as physical AI, the Internet of Things, and big data into its manufacturing processes. This enables smart monitoring and automated management, enhancing overall operational efficiency and product quality. To mitigate the impact of rapid temperature increase during mixing on the structural integrity and performance of the smart silica capsules, the factory has installed a customized smart temperature control system powered by physical AI to ensure stable product quality. The factory is also equipped with a human-machine interface (HMI), programmable logic controllers (PLCs), and clean-in-place (CIP) systems to boost production efficiency and flexibility. Additionally, it features an Industrial Internet of Things (IIoT) monitoring system to track change of temperature and volume and electricity usage in real time, optimizing energy management. It also adopts just-in-time (JIT) production management to reduce inventory backlog and resource waste, comprehensively promoting efficient smart manufacturing operations.By implementing lean management and the principles of smart manufacturing, APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization within a limited space. This achievement enables flexible small-batch customized production and achievies “Industry 4.0 1i Maturity,” paving the way for physical AI applications.Guests visiting the APEL Wisepura Aquapura Microfactory.Dual Advancement in Health and Environmental Technology InnovationWater is an essential resource for sustaining human life and ecological health. However, urban development has exacerbated water pollution, posing significant threats to public health and ecosystems. To address these challenges, APEL has developed Wisepura Aquapura, featuring the world’s first patented porous silica capsule technology. This innovation has received gold and silver medals at the International Exhibition of Inventions of Geneva in 2022 and 2024, respectively. It intelligently releases active ingredients upon contact with water, effectively eliminating over 95% of harmful microorganisms and antibiotic-resistant bacteria while also meeting diverse application needs. This technology has been widely applied across Hong Kong’s public infrastructure, targeting over 30 types of bacteria, fungi, and viruses in water supply, air conditioning, and sewage systems—including Legionella, hand-foot-and-mouth disease pathogens, influenza virus, and Candida albicans—significantly reducing the risk of waterborne and aerosol-transmitted diseases. Moreover, the silica capsule can be reused multiple times and safely disposed of at the end of its lifecycle, thereby minimizing environmental impact and setting a new standard for water treatment solutions.APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization, achieving “Industry 4.0 1i Maturity.”About Wisepura Aquapura MicrofactoryLocated in Kowloon Bay, the APEL Wisepura Aquapura Microfactory scales up laboratory processes to pilot production while effectively adapting to the spatial constraints of traditional multi-story industrial buildings in Hong Kong. It achieves a high production capacity of 6 tons per day. At the heart of the production line is its C-shaped layout, laying a solid foundation for efficient operations. The factory is equipped with mixing, filling, and screw capping systems, along with smart technologies, and a customized pipeline system that connects 5 pharmaceutical-grade mixing tanks, enabling comprehensive lean management. Due to the limited space, the factory is equipped with a 2.5-meter-high automatic capping machine that maximizes vertical space, demonstrating the perfect integration of space efficiency and smart technology.The launch of the Microfactory not only significantly enhances production efficiency but also accelerates APEL’s collaboration with Superpower Pumping Engineering Co., Ltd., facilitating the market expansion of research products. Furthermore, the Microfactory has received official orders from the Drainage Services Department, demonstrating strong recognition of its solutions and generating tangible economic benefits for the Company. To tap into the Japanese market, which places high value on personal health and environmental hygiene, APEL is currently holding an innovative interactive exhibition at The Lab. in Osaka to showcase its three flagship products—Wisepura water and air purification systems, GERMAGIC™ antimicrobial coating, and GERMAGIC™ PET health care solutions for pets—seizing growth opportunities in Asia’s health technology industry.About Yee Hop Holdings LimitedYee Hop Holdings Limited (stock code: 1662.HK) is a company listed on the Main Board of the Stock Exchange of Hong Kong Limited and a long established contractor in Hong Kong, principally engaged in the provision of foundation works and tunneling works. In addition, its associate company, Windmill Street Development, is engaged in the development of premium property projects in Birmingham, the United Kingdom. In 2023, the Group established Absolute Pure EnviroSci Limited (“APEL”), which focuses on health and environmental innovations, including the distribution and research and development of specialty biochemical and biomedical products. APEL has also established laboratories in collaboration with The Hong Kong University of Science and Technology (“HKUST”) and the Hong Kong Science Park successively. The joint laboratory, “HKUST-AP EnviroSci Ltd. Joint Laboratory on Health and Environmental Innovation,” was officially launched on 10 January 2024. Additionally, the “APEL Biomedical Technology Innovation and Translational Commercial Laboratory” located at the Hong Kong Science Park was officially inaugurated on 13 March 2024.For more information about Yee Hop Holdings, please visit: http://www.yee-hop.com.hk/About Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited (“APEL”), is an indirect non-wholly owned subsidiary of Yee Hop Holdings Limited, a company listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 1662.HK). With a mission to improve the quality of life and living environments, APEL is principally engaged in the research and development and commercialization of health and environmental innovations. Leveraging its Multilevel Antimicrobial Polymer (MAP-1) technology, APEL has developed specialized application formulas in four key areas: air purification in aircraft, water purification, livestock health, and eco-friendly building materials, all designed to address pressing global challenges. APEL looks forward to working with researchers and industry partners worldwide to drive further health and environmental innovations.For more information about APEL, please visit: https://apesl.com/For media inquiries, please contact:AJA (IR & Communications)Avy YuTel: +852 9500 4443Email: avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 7.4% to HK$1,576.9 million- Profit from continuing operations rose by 43.1% to HK$300.8 million- Net gearing ratio down to 8.3% from 12.2%- Recommended Final Cash Dividend of HK5.50 Cents Per Share and Special Cash Dividend of HK6.00 Cents Per Share- Continued enrichment of pipeline through R&D and strategic in-licensing- Improved operational efficiency by enhancing capacity and optimizing production leverage efficiencyHONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing, and sale of essential medicines and specialty drugs, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Building on the growth momentum of previous years, Jacobson Pharma continued to make promising progress, achieving total revenue of approximately HK$1,576.9 million during the Reporting Period, a year-on-year growth of 7.4%. Profit for the year from continuing operations increased by 43.1% to HK$300.8 million, reflecting the Group’s steadfast commitment to strategic execution and operational excellence.The Group’s financial position remains strong, providing a solid foundation for fuelling future development and dividend returns to shareholders. Bolstered by a robust business performance and persistent cost management, the Group achieved an adjusted EBITDA of HK$572.8 million. Net gearing ratio improved to 8.3% from 12.2% at the close of FY2025, and cash reserves held steady at HK$509.0 million.The Board recommends the payment of a final cash dividend of HK5.50 cents per share (FY2024: HK3.00 cents per share) and a special cash dividend of HK6.00 cents per share (FY2024: Nil). Including the interim cash dividend of HK3.50 cents per share already paid, the total cash dividend for FY2025 would be HK15.00 cents per share (FY2024: HK5.50 cents per share), up by 172.7% year-on-year.Robust Portfolio Meets Rising Healthcare DemandThe Group’s sales growth in FY2025 was driven by multiple factors. Hong Kong’s extended flu season, compounded by circulating respiratory pathogens, led to a significant surge in demand for cold and flu treatments. Broader healthcare trends further supported this momentum, including an aging population, high rates of chronic conditions like diabetes and hypertension, and growing mental health needs. Additionally, public health initiatives heightened awareness of preventive care, reinforcing demand for medications and medical consultations. Together, these trends contributed to sustained sales momentum across the Group's businesses throughout the Reporting Period.The Group remains well-positioned to meet Hong Kong’s growing healthcare needs with its broad portfolio of essential medicines and specialty drugs. Backed by an efficient supply chain, it ensures reliable access to cost-effective treatment choices while reinforcing its role as a trusted healthcare service provider.Sustained R&D Momentum and Specialty Portfolio ExpansionMomentum in expanding the Group’s R&D pipeline of the Group was sustained throughout the Reporting Period, advancing its strategy to broaden the product portfolio. As of 31 March 2025, the pipeline comprised 219 products at various development stages.To expand its specialty drugs portfolio, the Group concluded various in-licensing agreements with global manufacturers for 20 high-performing products across key therapeutic areas such as immunology, oncology, cardiology, neurology, and rare diseases. Selected for their strong clinical profiles and market potential, these additions support sustained growth and reflect the Group’s commitment to advancing patient care through innovative therapies.Bringing Innovation to Enhance Patient OutcomesThe Group continues to expand market reach for Arsenic Trioxide Oral Solution, co-developed with The University of Hong Kong to treat acute promyelocytic leukaemia (APL). Clinical trials show a 97% survival rate and 100% molecular remission, earning it the Orphan Drug Designation from both the U.S. FDA and EMA. A global Phase III trial will be launched in 2026 with market approval targeted for 2028.Jacobson Pharma also achieved a significant milestone on 20 February 2025, with the launch of supply chain liaison services for Axicabtagene Ciloleucel (Yikaida) – a CAR-T therapy - in partnership with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Fosun Kairos Biotechnology Inc.. Supported by an Advanced Therapeutic Product (ATP) logistics license, this breakthrough therapy for diffuse large B-cell lymphoma marks a major advance in next-generation cancer care.Powering Growth with Smart ProductionIn line with the Groups’ strategic goal of enhancing its manufacturing capabilities, Jean Marie Pharmacal Co Limited, a member of the Group, commenced the development of a new pharmaceutical facility at Tai Po InnoPark in February 2025. Supported by the Hong Kong Government’s New Industrialisation Acceleration Scheme, the facility will house 10 smart production lines for sterile eye drops, solid dosage forms, and oral liquids. Leveraging AI, robotics, and real-time analytics, the advanced facility will boost production efficiency and quality standards. Trial production is slated for late 2026, with a focus on developing specialty products to cater to unmet medical needs. This investment strengthens the Group’s industry leadership and supports Hong Kong’s emergence as a hub for advanced pharmaceutical manufacturing.Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, stated, “FY2025 has been another eventful year for Jacobson Pharma, underscoring the strength of our strategy, the dedication of our team, and the trust of our stakeholders. These foundations continue to position us as a leading force in Hong Kong’s generic pharmaceutical sector.Looking to 2026, we remain optimistic about our prospects and growth. Healthcare policy reforms and rising medication demand from an aging population and chronic conditions will fuel the growth of the generic drugs market. With a strong pipeline, expanding partnerships, and digital innovation, we are well-positioned to seize growth opportunities and create sustainable values for the Group’s businesses”About Jacobson Pharma Corporation Limited (Stock Code: 2633)Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 9 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.The Group is committed to strategically enhancing its portfolios by introducing high-value-added specialty products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com Copyright 2025 ACN Newswire via SeaPRwire.com.

PIONEERTOWN, CA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - ESCAPE Records releases two transcendent works from its secretive Mojave Desert hub in Pioneertown CA: the Parallel Universe EP, a genre-defying musical odyssey from touring electronic artists and industry veterans, and Gong Song! (Live from Escape, Pioneertown CA), a 45-minute sound healing masterpiece by Alessandra Montana.Naturally Occurring Emoji - BEEPLEEveryday from BEEPLE. Cover of Parallel Universe EP. Courtesy of Escape Records LLC.Crafted where social media fades to the obscure and creativity thrives, these two new records aim to forge deep audience connections - inspiring a sense of solidarity between the creative and their audience.The Parallel Universe EP blends electronic, Americana, and Latin vibes, born during a songwriting retreat at ESCAPE's legendary studio, some 40 miles from the gates of Coachella in the high desert of California, a mile above sea level under a myriad of stars. Listeners are invited to ponder what their life would be like in a parallel universe; evoking poignant emotions in today's somewhat turbulent world.Tracks are shared by studio founder and producer ROC Gardner, Latin Grammy-nominated Cimafunk (La Vida), Jamie N Commons (Hold Me While You Wait), DJ Tennis (Life and Death), and Grammy-nominated Jan Blomqvist (Remote Control), joined by producers Joseph Ray (Nero), Daniel Cantisani, Nikko Gibler (RicoshÄ“i), and Devlin Thorn alongside artists that include Kim Bullard (Elton John) and Craig McClune (David Gray) who lent their expertise to evolving the tracks.Mixed by Mick Guzauski (Daft Punk, The Weeknd, Michael Jackson) and mastered by Bernie Grundman, tracks include Mezcalita (June 13), Happy Unhappy (June 20), La Sugar (June 27), and Never Know (July 4). BEEPLE's surreal artwork Naturally Occurring Emoji and an AI-driven video by The Dor Brothers amplify the EP's cosmic narrative."The universal sky we spent each night under sparked something raw," says ROC. "It was awesome breaking out of our channels - we got to capture all these ideas, unbound by trends or any other concerns - it was great fun!"Simultaneously, Alessandra Montana's Gong Song! (Live from Escape) captures a live 45-minute sound journey, recorded meticulously with vintage gear and microphones at ESCAPE. Guided by mixing engineer Rob Columbus and mastered by Grundman, Montana's gongs and sacred instruments weave a meditative portal for healing."Escape's magic let me share my practice globally. I can't wait for people to hear this and experience the journey we went on," says Montana.ESCAPE, a 140-acre creative haven hosting Rüfüs Du Sol, Arctic Monkeys, Usher, RAYE - and many others - fosters unfiltered artistry. The studio hopes to deliver magic - and its music - unfettered and unfiltered.Visit www.esca.pe for more.Assets: Press release, artwork, lyrics, .wav files available upon request.Interviews: info@esca.peJan Blomqvist appears courtesy of Armada Music B.V.Tracks:Mezcalita (1st Single): https://audiosalad.ffm.to/commons-roc-mezcalitaParallel Universe EP: https://audiosalad.ffm.to/parallel-universeGong Song! (Live from Escape): https://audiosalad.ffm.to/gong-songContact InformationSteven Bradley9/9 - Digital/Social Mediaescape@9slash9.comEscape RecordsLabel Contactinfo@esca.peSOURCE: Escape Records LLC Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 达丰设备服务有限公司（"达丰"或"公司"，连同其附属公司统称"集团"）（股份代号：2153）为在中国成立的首家外资塔式起重机服务供应商，公布其截至2025年3月31日止年度（"2025财年"或"年内"）的全年业绩。2025财年，集团的收益为人民币634.6百万元（2024财年：682.3百万元）。公司权益持有人应占亏损为人民币120.5百万元（2024财年：95.6百万元）。亏损增加主要是由于于(i)经济增长放缓及建筑业不景气导致收入下降；及(ii)递延税项调整导致所得税开支增加。截至 2025 年 3 月 31 日，集团全年平均管理的塔式起重机总数为1,180台。集团的使用总吨米由截至2024年3月31日止年度的3,178,404减少至截至2025年3月31日止年度的3,137,910。于2025年3月31日，集团有256个在建项目，未完成合同总价值约为人民币721.4百万元，手头项目共有38个，预计合同总价值约为人民币78.7百万元。于本财政年度内，在市场需求不足及塔式起重机每吨米平均每月服务价格下降的影响下，供需失衡导致整个工程机械行业面临激烈的市场竞争。为应付市场疲弱情况，集团因时制定不同战略，并不断地调整业务占比，逐年降低房地产行业的收入占比。集团积极回应国家提出的大力发展清洁能源的号召，并应市场发展趋势及发展潜力，专注于火电项目和核电项目。而清洁能源项目施工期长，规模大，集团依靠丰富的行业经验，成熟的施工技巧以及雄厚的技术实力取得相当的优势。于2025财年，集团加快推进境外市场的布局，通过大湾区和印尼深入贯彻集团运营策略，逐步扩大大中型塔式起重机机队。截止目前，香港和印尼的项目多半为大吨米塔机。由于以上原因，清洁能源和境外项目依旧是集团未来的发展重点。年内，集团继续投资于数字化管理平台及新的塔式起重机技术解决方案的研发。于2025年3月31日，集团拥有187项塔式起重机相关的实用新型及发明注册专利。雄厚的技术实力将继续助力集团获得项目，而在塔式起重机技术解决方案方面的研发能力提升将增强集团交付卓越服务的能力。达丰设备服务有限公司行政总裁邱国燊先生表示："除了房地产市场和建筑行业的低迷外，地缘政治紧张局势和人民币贬值压力进一步削弱了中国经济。为应对这些经济挑战和瞬息万变的营商环境，我们迅速调整了发展战略，包括拓展清洁能源建筑领域，并将地域范围扩展至大湾区及印尼。我们相信，这些举措的积极影响将在未来几年逐步显现。"达丰设备服务有限公司主席黄山忠先生总结："即使身处最艰难的环境，我们始终坚守初心。秉承'厚德、安全、卓越'的核心价值观，我们将在业务发展中持续追求卓越。在下一财年中，我们将进一步巩固在清洁能源及新市场的优势地位，把握市场新机遇，同时专注于塔式起重机新技术的研发，使我们具备最强大的技术能力，为客户提供卓越的服务。此外，我们还将持续推进资源共享及降本增效等举措。透过上述措施，我们相信，我们能够实现集团的企业愿景'做最好的建筑设备服务供应'。" Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 随着国家「新质生产力」成为推动高质量发展的重要策略，义合控股有限公司（「义合控股」；香港主板上市编号：1662）旗下附属公司 Absolute Pure EnviroSci Limited（「APEL」或「本公司」）积极响应国家政策，携手香港生产力促进局（「生产力局」）共同建设智能微工厂，在香港实现Wisepura Aquapura多孔结构硅微囊专利技术产业化，推动香港智能制造和新型工业化。今年 3 月开幕的生产力局「生命健康科技馆」展示了逾 20 项由生产力局、InnoHK研发平台、本地大学及业界携手研发的科技成果及创新应用，包括Wisepura Aquapura多孔结构硅微囊专利技术。全球首个Wisepura Aquapura智能微工厂全面投入生产运营作为双方合作的重要成果，APEL 与生产力局合作建设的全球首个Wisepura Aquapura智能微工厂于 2025 年 6 月 13 日香港九龙湾正式启用，标志着「工业 4.0」的第一阶段正式落地和 APEL 科研成果产业化发展的重要里程碑。在投资界和商界众多嘉宾的见证下，义合控股主席詹燕群先生、APEL 主席钟伟强博士及 APEL 董事杨学光博士于启用典礼上共同为 APEL Wisepura Aquapura智能微工厂揭幕，正式宣告其投入生产运营。APEL 董事杨学光博士（左一）、义合控股主席詹燕群先生（左二）、生产力局总裁毕坚文先生（右二）及APEL 主席钟伟强博士（右一）于Wisepura Aquapura智能微工厂启用典礼合照。APEL 主席钟伟强博士表示：「我们非常荣幸可以与生产力局合作建设Wisepura Aquapura智能微工厂，并衷心感谢生产力局对 APEL 的支持，充分印证了我们在生命健康科技领域深厚的科研实力与创新能力。APEL Wisepura Aquapura智能微工厂的正式投产，提升了我们应对市场日益增长需求的能力，为公司发展注入新动能。展望未来，我们将持续拓展合作伙伴网络，积极拓展国际版图，致力将本地科研成果推向全球，为全球健康与环境保护贡献力量，携手共创可持续发展的美好未来。」APEL 主席钟伟强博士于启用典礼致辞。与山湖集团建立战略合作关系，共拓大湾区水质净化及水产养殖科技新机遇广东山湖集团有限公司（「山湖集团」）作为全球领先的室内空气环境处理专家，其核心产品大厦扇畅销全球六大洲，服务超过5,000万用户。十年前，山湖集团旗下公司山湖机电前胆性地投入研发智能节能养殖机械科技。2025年6月13日，APEL与山湖集团正式签署战略合作备忘录，共同进军水质净化治理及智能水产养殖领域。双方计划开发对水质净化设备、生态修复技术、智能监测系统等有较大需求的包括各类环保工程项目，如河道治理、黑臭水体整治、生态修复等环保工程市场。对新型过滤材料、水处理工艺、水质监测技术等有稳定需求包括城市污水处理厂、工业园区污水处理设施的市政污水处理市场。与政府环保部门、市政工程公司建立合作关系，参与污水处理项目的招投标，提供定制化解决方案。合作内容涵盖技术研发、市场拓展及资源共享。双方将联合开发智能水质监测系统，利用大数据及人工智能优化养殖决策，并针对环保工程、市政污水处理等市场推广高效净化技术。合作项目将深度融合山湖集团在机电设备与消毒技术的产业优势，以及APEL旗下Wisepura Aquapura智能微工厂的先进水处理专利技术。此合作为期一年，期满后可自动续约，通过双方商业及技术资源技术交流会，合作成果将率先在粤港澳大湾区推广应用，有望推动大湾区环保与水产养殖产业升级，带动产业链的升级转型，展望未来将逐步拓展至海外市场。APEL（左）与山湖集团签署战略合作备忘录。迈向「工业4.0」智能制造新时代在推动「工业 4.0」的进程上，APEL Wisepura Aquapura智能微工厂将人工智能、物联网、大数据等先进技术整合到制造流程，实现智能监控与自动化管理，提升整体运营效率与产品品质。为解决混合过程中温度急升对智能硅微囊结构和性能的影响，工厂安装了一套由物理人工智能（Physical AI）驱动的定制智能温控系统、工厂更配备人机介面（HMI）、可程式设计逻辑控制器（PLC）及在位清洗（CIP）系统，以提升生产效率与灵活性。此外，工厂引入工业物联网（IIoT）监控系统，实时监测用电情况，有效优化能源管理；同时透过及时化生产管理（JIT）有效减少仓库积压及资源浪费，全面推动智能制造的高效运营。一众嘉宾参观 APEL Wisepura Aquapura智能微工厂。健康与环境科技创新双重升级水资源是维系人类生命与生态环境健康的关键，但随着城市发展，水污染问题日益严重，对公共卫生和生态系统构成重大威胁。为改善水质，APEL 研发的Wisepura Aquapura采用了全球首创、并于 2022 年及 2024 年荣获日内瓦国际发明展一金一银奖项的多孔结构硅微囊专利技术。该技术能在与水接触时智能控释其活性物质，有效消灭逾 95%的有害微生物及耐药性细菌，同时满足多样化的应用需求。这项创新技术已广泛应用于香港多个公共基础设施，有效针对供水系统、空调系统及下水道系统中超过 30 种细菌、真菌及病毒，包括退伍军人症、手足口病原体、流感病毒及白色念珠菌等，显著减低水系统及气溶胶传播疾病的风险。此外，硅微囊系统可多次循环使用，且在使用寿命结束后亦能安全弃置，降低环境负担，为水质处理解决方案树立新标准。通过精益管理及智能制造的概念，APEL 全球首个Wisepura Aquapura智能微工厂在有限的空间内成功整合了定制的生产技术、机械自动化和数据可视化，实现灵活小批量定制生产和「工业 4.0 的 1i 成熟度水准」，为 Physical AI 的应用铺平了道路。APEL 全球首个Wisepura Aquapura智能微工厂成功整合了定制的生产技术、机械自动化及数据可视化，实现了「工业 4.0的 1i 成熟度水准」。关于APEL Wisepura Aquapura智能微工厂位于九龙湾的 APEL Wisepura Aquapura智能微工厂将实验室规模的工艺放大至中试规模，并巧妙适应香港传统多层工业建筑的空间限制，成功实现每日6吨的高效产能。生产线的核心在于其 C 形布局设计，为高效运作奠定基础。工厂配备混合系统、灌装及旋盖系统，以及智能化设置，并透过定制的管道系统连接 5 个药用级混合罐，实现全流程精益管理。针对有限空间，工厂特别配备了一台 2.5米高的自动上盖机，充分利用立面空间，展现空间利用与智能化的完美结合。智能微工厂的启用和投产，不仅大幅提升了生产效率，也加速了 APEL 与力霸水泵机械工程有限公司的合作进程，促进科研产品的市场拓展。此外，智能微工厂已获渠务署正式订单，彰显其解决方案获得高度认可，并为公司持续带来实质经济效益。为布局日本这个高度重视个人健康与环境卫生的市场，APEL 现正于大阪 The Lab.举行创新互动展览会，展示三大旗舰产品 - Wisepura水质及空气净化系统、GERMAGICTM抗菌涂层和 GERMAGICTM PET 宠物健康及护理方案，把握亚洲健康科技产业的发展机遇。关于义合控股有限公司义合控股有限公司为香港主板上市公司（1662.HK），是香港一间历史悠久的承建商，主要从事提供地基工程及隧道工程业务。此外，旗下联营公司 Windmill Street Development 于英国伯明罕发展优质物业项目。集团于 2023 年成立 Absolute Pure EnviroSci Limited （「APEL」），主要从事健康及环境创新业务，包括特种生化及生物医药产品之分销及研发业务，并先后与香港科技大学及香港科学园成立实验室。其中「香港科技大学-AP EnviroSci Ltd.环境科学健康与环境创新联合实验室」之联合实验室于 2024 年 1 月 10 日启用，而位于香港科学园之「APEL生物医药科技创新及转化商业实验室」亦于 2024 年 3 月 13 日正式启用。欲知更多有关义合控股有限公司资料，请浏览网页：http://www.yee-hop.com.hk/关于 Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited（「APEL」）为香港联合交易所主板上市公司-义合控股有限公司（香港主板上市编号：1662）的间接非全资附属公司。以改善生活品质及居住环境为使命， APEL 主要从事健康与环境科技创新的研究、开发及商业化。基于其多层次杀菌涂层技术（MAP-1），APEL 已在四个关键领域：飞机空气净化、水质净化、畜牧健康和环保建材，研发专门的应用配方，旨在应对全球迫切挑战。APEL 期待与全球研究人员和行业伙伴合作，推动更多健康与环境科技创新。欲知更多有关 APEL 资料，请浏览网页：https://apesl.com/传媒如有查询，请联络：AJA (IR & Communications)庾婉华电话：+852 9500 4443电邮：avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

业绩亮点- 收入增长7.4%至15.8亿港元- 来自持续经营业务的溢利增长43.1％至3.0亿港元- 净资本负债比率由12.2％下降低至8.3％- 建议派发现金末期股息每股5.50港仙及现金特别股息每股6.00港仙- 持续通过研发及策略引进授权丰富产品线- 透过提高生产设施营运效率及杠杆，促进运营效率香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 从事基础药物及专科药物研发、生产、市场推广及销售的领先企业 ─ 雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633.HK）今天公布公司及其附属公司（统称「集团」）截至二零二五年三月三十一日止年度（「二零二五财年」或「报告期」）的全年业绩。承接过去数年的稳健增长势头，雅各臣于本财政年度持续录得可观表现，纵使面对持续的宏观经济挑战，全年收入约为15.8亿港元，按年增长7.4%。持续经营业务的溢利飙升43.1%，达至3.0港亿元，充分体现集团坚守卓越营运及策略执行的成效。集团财务状况保持强健，为推动未来发展及股息回报提供坚实基础。在强劲业务表现及持续成本管理的支持下，集团于报告期内录得经调整EBITDA约5.7亿港元。净资本负债比率由12.2％降至二零二五财年末的8.3％，现金储备约为5.1亿港元，维持稳定水平。董事会建议派付现金末期股息每股5.50港仙（二零二四年财年：每股3.00港仙）及现金特别股息每股6.00港仙（二零二四年财年：无）。包括已派付的现金中期股息每股3.50港仙，二零二五财年的现金股息合共每股15.00港仙（二零二四财年：每股5.50港仙），按年上升172.7％。多元产品组合满足不断上升的医疗需求集团于二零二五财年的销售增长受多项因素推动。香港经历漫长的流感季节，加上多种呼吸道病原体同时活跃，带动对伤风感冒药物的需求大幅上升。人口老化，加上糖尿病及高血压等慢性疾病高发，以及精神健康需求日益增加等，进一步推升医疗需求的趋势。此外，公共卫生计划提高了公众对预防保健及早治疗的意识，增加对药物和就诊需求。在这些因素共同作用下，集团整体业务于报告期内维持销售增长。凭借丰富的基础药品及专科药物组合，集团继续具备优越的条件，满足香港不断增长的医疗需求，而透过高效的供应链，集团能够提供具成本效益的治疗选择，进一步巩固其作为香港值得信赖医疗服务供应商地位。持续推进研发与拓展专科药物组合集团于报告期内持续推进研发管线扩充，贯彻产品组合拓展战略。截至二零二五年三月三十一日，集团的研发项目包括219项处于不同开发阶段的产品。为扩大专科药物组合，集团与多家国际药厂签订授权协议，引进20项高效药物，涵盖自身免疫性疾病、肿瘤、心血管疾病、神经疾病及罕见病等多个治疗领域。这些新增药物具有出色的临床表现和市场潜力，不仅支持集团持续增长，更体现集团致力以创新疗法改善患者生活质量的承诺。以创新科技提升治疗成效集团持续扩大三氧化二砷口服液（Arsenol）的市场覆盖，该产品用于治疗急性早幼粒细胞白血病（APL），由集团与香港大学联合开发。临床试验显示，该疗法的存活率为97%，分子学缓解达100%，因而获美国食品药品监督管理局及欧洲药品管理局认定为罕见病用药。全球第三期试验将于二零二六年开始，目标是于二零二八年获上市批准。集团亦于二零二五年二月二十日达成另一重大里程碑 - 与上海复星医药（集团）股份有限公司及Fosun Kairos Biotechnology Inc. 合作，推出CAR-T疗法Axicabtagene Ciloleucel (商品名：Yikaida) 的供应链协调服务。此疗法专为治疗弥漫性大B细胞淋巴瘤而设，并已获发先进治疗产品（ATP）物流牌照，标志着集团在下一代癌症疗法领域迈出重要一步。智能生产驱动产能为配合集团提升制造能力的策略目标，集团旗下公司正美药品有限公司（Jean Marie Pharmacal Co. Limited）已于二零二五年二月于大埔创新园展开全新制药设施的建设工作。在香港政府「新型工业加速计划」的支持下，该厂房将配备十条智能生产线，用于生产无菌眼药水、固体剂型药物及口服液，通过AI、机器人及实时数据分析，提升生产效率及质量水平。试产计划预计于二零二六年底展开，重点生产专科治疗药物，针对未被满足的医疗需求。此项策略性投资不仅巩固本集团的行业领导地位，更有助推动香港发展成为先进药业制造枢纽。雅各臣主席及行政总裁岑广业先生表示：「二零二五财年对雅各臣而言是充满意义的一年，再次印证我们策略的前瞻性、团队的坚毅与投入，以及持份者对我们的信任。这些坚实基础，持续巩固我们作为香港仿制药市场领导者的地位。展望二零二六年，我们对业务前景充满信心。随着医疗政策改革推进，以及人口老化与慢性病带动药物需求上升，将持续推动基础药物市场增长。凭借强大的产品线、不断拓展的合作伙伴关系，以及数码创新，我们已具备有利优势，把握增长机遇，为集团业务创造可持续价值。」关于雅各臣科研制药有限公司（股份代号：2633）雅各臣是本地领先的医药公司，拥有垂直整合的业务，包括基础药物及专科药物的研发、生产、分销、销售及物流。作为本地主要的非专利药供货商，集团在香港私营及公营领域，具有最广泛的销售及分销的市场覆盖，并积极向策略性选择的亚洲市场伸延扩展。集团于香港设有9间PIC/S GMP认证的非专利药生产设施，并在各种治疗药物类别中拥有广泛的产品组合与享有优越市场地位。同时，集团一直致力透过增加各种高增值产品，策略性地扩大其非专利药的产品组合。扎根香港，集团已于中国、澳门、台湾及柬埔寨开设营运子公司，建立区域性商业平台，以把握亚太区及大中华地区的市场潜力。而自 2017 年 6月 1 日，集团获纳入 MSCI 香港微型股指数成份股。更多详情请浏览臣科研制药有限公司网站： http://www.jacobsonpharma.com Copyright 2025 亚太商讯 via SeaPRwire.com.

- 「创业快綫」终极决选10间优胜初创顺利诞生，绿创能源有限公司夺得「环境、社会、企业管治大奖」，安神生物科技有限公司夺得「我最喜爱初创大奖」- 「创业快綫」终极决选日邀请到逾200名业界人士参与，助初创建立人脉及增加曝光，持续推动本港创业生态圈发展- 本届优胜初创业务主要集中于健康科技，亦有多间来自绿色科技、智慧城市及人工智能等领域香港，2025年6月13日 - (亚太商讯 via SeaPRwire.com) - 香港贸易发展局（香港贸发局）举办的第八届初创培育计划「创业快綫」终极决选顺利完成，10间优胜初创诞生。大会今年继续设有「环境、社会、企业管治大奖」(ESG Award)，表扬最具可持续发展及社会效益的初创企业，最终由绿创能源有限公司嬴得此奖项。至于现场观众一人一票选出的「我最喜爱初创大奖」，则由安神生物科技有限公司夺得。10间优胜初创将可参与一系列由贸发局组织的本地及海外的商贸活动，全面建人脉、拓市场、增曝光、觅伙伴。贸发局全力支援及推动初创企业发展，协助他们进军海外及内地市场，推广香港创科优势。香港贸发局商品贸易及创新总监兼对外事务总监黄燕表示： 「『创业快綫』作为香港贸发局的旗舰初创培育计划，一直推动本港最具潜力及创新的科技初创茁壮成长，致力协助本地初创提升实力及建立人脉，开拓新市场同时寻找商业及融资伙伴，并提升品牌知名度。自2018启动计划以来，我们已协助70间本地初创提升规模，同时扩展业务至海外市场，不少已取得卓越成就及赢得国际奖项，得到重大投资及建立重要的商业伙伴关系，充份体现这个平台加速推动香港初创成功发展。」第八届「创业快綫」报名公司超过200间，反应踊跃。十间优胜初创业务主要集中于健康科技，亦有多间来自绿色科技、智慧城市及人工智能等领域。今年「创业快綫」终极决选日吸引逾200位业界人士参与，包括一众投资者及商界领袖，现场亦设有初创展览，由「创业快綫」入围初创向与会人士进行业务介绍。贸发局将为优胜初创提供多元化商贸交流及配对活动晋身「创业快綫」最后20强的初创，在今天的终极决选上简介业务及创业理念，在现场接受评判的即场提问及评分，最终胜出的10间优胜初创分别为：ACTuWISE Limited、Decennium Platforms Limited、安神生物科技有限公司、Digitoe Limited、世美拉有限公司、汤宏健康科技有限公司、Firefilm Group Limited、艾柏轮科技有限公司、Entoptica Limited及绿创能源有限公司。（请按此下载完整得奖名单及初创简介）香港贸发局将为优胜初创安排一系列的交流考察及推广活动，与潜在投资者、买家和合作伙伴会面。评判赞赏优胜初创紧贴市场发展及决选表现评判之一阿里云(亚太北区)资深顾问车品觉表示：「每届新入选的初创都给我们带来惊喜，面对AI迅速发展，不少企业都迅速将AI融入实体业务，可见本地初创人才紧贴市场趋势，同时具备创新思维及一定实力。」另一评判香港初创企业协会主席杜伟樑亦表示：「本届参赛初创质素颇高，提供的产品及服务牵涉不同科技领域，特别是在人工智能、绿色科技和医疗创新等方面。我们乐见新一代初创在创新及科技各范畴都持续推陈出新，为社会整体发展出一份力，展现出无限潜力和创造力。香港初创持续蓬勃增长，去年香港初创企业已达4,694间再创新高，显示香港的营商吸引力有增无减，继续是设立初创的理想地点，前景亮丽，相信今年的优胜初创将可透过『创业快綫』获得更多拓展市场及建立人脉的宝贵发展机会。」「创业快綫」助初创取得公司投资及合作机会「创业快綫」为初创提供全面的宣传机会，优胜初创企业将可亲身参与内地及海外的展览会，以及与本地及世界各地的投资者会面接洽等，从而了解更多行业动态、海外市场趋势及投资者取向，以建立商脉和拓展市场及业务。上届优胜初创之一途龄科技(Libpet Tech)最近更完成了300万美元的种子轮融资，筹集所得资金将用于技术升级及拓展国际市场。途龄科技行政总裁徐华峰表示：「参加『创业快綫』成功为公司增加曝光及提升品牌知名度，获得不少潜在客户及投资者关注，在此十分感谢投资者对公司的信心。公司将携手公私营合作伙伴，将机器人技术融入日常生活，推动以人为本的智慧出行。」第四届「创业快綫：国际篇」12月举行 全球初创大比拼香港贸发局一直致力加强本地与海外创业生态圈的交流，巩固香港致力作为亚洲创科枢纽的竞争优势。于2022年首度举行的「创业快綫：国际篇」，过去三届吸引环球各地如澳洲、法国、德国、日本、韩国、土耳其、新加坡、阿联酋及美国等地的初创报名。第四届「创业快綫：国际篇」今年将继续在12月初的「创业日」举行，协助胜出的海外初创落户香港，并透过香港的平台探索大湾区及其他内地市场。「创业快綫」网页：https://portal.hktdc.com/startupexpress/tc/图片下载：http://bit.ly/4jPwedc10间「创业快綫」优胜初创企业顺利诞生，得奖初创代表与评判及嘉宾一起合照。后排由左至右为：阿里云（亚太北区）资深顾问车品觉、兴迅集团主席兼董事总经理张益麟、道源资本集团首席执行官陈甄灏、香港贸发局商品贸易及创新总监兼对外事务总监黄燕、Betatron Venture Group管理合伙人兼执行长Matthias Knobloch、PRD初创投资主席汤雷、香港初创企业协会主席杜伟樑。「创业快綫」终极决选请来中小学生到场展示不同科创方案，由2023年优胜初创 Big Bang Academy 联合创办人唐蒨怡提供指导及颁发奖状。「创业快綫」终极决选邀请逾200名业界人士参与，让初创与投资者和商界领袖等一起交流。「创业快綫」终极决选现场设有初创展览，入围初创为与会者介绍公司业务。香港贸发局新闻中心：http://mediaroom.hktdc.com/tc传媒查询新闻界如有查询，请联络香港贸发局传讯及公共事务部：苏显博 电话：(852) 2584 4049 电邮：stanley.hp.so@hktdc.org黄家欣 电话：(852) 2584 4524 电邮：katy.ky.wong@hktdc.org张希汶 电话：(852) 2584 4272 电邮：serena.hm.cheung@hktdc.org刘茸 电话：(852) 2584 4472 电邮：clayton.y.lauw@hktdc.org香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。 Copyright 2025 亚太商讯 via SeaPRwire.com.